Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.
Leptomeningeal Metastasis|Lung Cancer
DRUG: Nimotuzumab
progression free survival, From the diagnosis of the LM to the time of disease worsen, 2 years
Overall Survival, From the diagnosis of theLM to the time of death, 2 years|Incidence of Treatment-Emergent Adverse Events, When the Nimotuzumab is used,we will observe if the patients have the allergic reaction,diarrhea ,vomiting and so on.Number of participants with treatment-related adverse events as assessed by CTCAE v4.0", 8Weeks
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.